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Abstract Thrombosis of the inferior vena cava is a life-
threatening complication in cancer patients leading to
pulmonary embolism. These patients can also be affected
by superior vena cava syndrome causing dyspnea followed
by trunk or extremity swelling. We report the case of a 61-
year-old female suffering from an extended colorectal tu-
mor who became affected by both of the mentioned com-
plications. Due to thrombus formation within the right vena
jugularis interna, thrombosis of the inferior vena cava, and
superior vena cava syndrome, a combined interventional
procedure via a left jugular access with stenting of the
superior vena cava and filter placement into the inferior
vena cava was performed As a consequence, relief of the
patient’s symptoms, prevention of pulmonary embolism,
and paving of the way for further venous chemotherapy
were achieved.
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Introduction
In industrial nations like the United States, colorectal
cancer is the second leading cause of death from cancer [1].
Such a systemic disease may lead to a 4.1-fold elevated
risk of a venous thrombosis [2]. The chance of a venous
thromboembolism (VTE) is specifically high in patients
treated with a combination of fluorouracil and leucovorin
calcium because of colorectal cancer (15% of patients were
affected) [3]. The 1-year survival rate of cancer patients
afflicted by such an event is 12%, versus 36% in patients
without embolism [4]. Pathogenetic mechanisms of hy-
percoagulability are the production of procoagulants and
the activation of endogenous prothrombotic factors by the
tumor itself [5, 6].
Besides liver and lung metastasis, colorectal cancer can
also affect the adrenal gland, which constitutes only 13.5%
of all adrenal metastasis of primary tumors [7]. More
common in renal cell carcinoma or adrenocortical carci-
noma, an adrenal metastasis of a colorectal cancer can also
invade the inferior vena cava (IVC), causing a dangerous
situation requiring intervention, like a vena cava filter, to
prevent pulmonary embolism [8, 9].
Another rare complication of colorectal cancer is supe-
rior vena cava syndrome (SVCS), causing obstruction of
the superior vena cava (SVC) [10]. Owing to its thin wall
and the low intravascular pressure, the SVC has only a low
resistance to an extrinsic compression, and thrombus for-
mation is easily possible. This may result in congestion and
edema of the face and upper thorax, as well as symptoms
like dyspnea, dysphagia, cognitive dysfunction, and head-
ache. Therapeutical options for patients with SVCS having
already received chemotherapy and radiation therapy are
limited. Venous stenting is usually helpful in such pallia-
tive situations, where life quality is paramount, due to the
simplicity of the procedure and rapid relief of symptoms
[11].
This rare case therefore highlights the subsequent
management of SVCS and IVC thrombosis with stent
placement and filter insertion in a patient with metastatic
rectal cancer to relieve symptoms, prevent pulmonary
embolism, and pave the way for port implantation.
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Case Report
Our institutional review board does not require approval for
publication of retrospective case reports. A 61-year-old fe-
male with a history of metastatic rectal cancer was referred to
our hospital for surgical port implantation. In the distant past,
primary staging had yielded malignant pulmonary and
mediastinal spread, and the patient preoperatively underwent
two cycles of chemotherapy combined with external-beam
radiotheratpy (45 Gy) to the rectum. Four months after pri-
mary diagnosis, a complete mesorectal excision and low
anterior resection with colorectal anastomosis was carried
out by our visceral surgeons. The pathological analysis re-
vealed a pT3, pN1, M1, G2 stadium of the tumor. Three
months after surgery, suspicion of metastases of the liver was
confirmed by magnetic resonance imaging of the abdomen
showing two lesions in segments V/VI with a diameter of 5.4
cm and VII/VIII with diameter of 1.7 cm. As a consequence,
hemihepatectomy of the right lobe was scheduled 1 day later.
The situation seemed to be stable, when a PET-CT scan
exposed a progression of the pulmonary and mediastinal
lesions 21 months later. These findings led to an expansive
resection of the right lung by our thoracic surgeons (upper
lobe resection, two-times atypical resection of the middle
lobe, two-times atypical resection of the lower lobe, medi-
astinal retrocaval lymphadenectomy), with an R0 situation
of all metastases, except for the retrocaval manifestation,
with an R1 situation. One day postoperatively, CT showed a
thrombosis of the right internal jugular vein and the right
brachiocephalic vein. Treatment of venous thrombosis was
initiated with oral anticoagulation therapy. Over the next 3
months, increasing symptoms of SVCS with swollen head
and arm veins, headache, dyspnea, and livid face occurred.
Another CT examination was performed that further exhib-
ited thrombosis of the right internal jugular vein and the right
brachiocephalic vein, but also recurrent mediastinal tumor
spread and new onset of an inhomogeneous hypodense
metastatic lesion of the right adrenal gland with an extent of
7.0 · 7.2 cm. As a consequence, the Department of Oncology
was consulted and recommended palliative chemotherapy
according to the FOLFOX scheme. On the grounds of the
oral anticoagulation and thrombosis, no port could be in-
stalled, and the first cycle of chemotherapy had to be ar-
ranged via a peripheral access.
One month later, due to persisting symptoms and the fact
that an efficient port would be a major part of the continuing
therapy, the patient was referred to our interventional radi-
ology department for SVC stent implantation. The major
intention of this approach was to relieve symptoms and
contemporaneously pave the way for port implantation. At
this point in time oral anticoagulation had been stopped. We
initiated a follow-up CT to evaluate the actual situation be-
fore stent implantation. The scan showed that the metastasis
of the adrenal gland now reached 7.2 · 8.4 cm, with tumor
invasion into the right suprarenal vein and renal vein, and
with luminal compression of the IVC to 50% with partial
concomitant thrombosis (Fig. 1). Moreover, the mediastinal
tumor mass was now compressing the confluence of the right
brachiocephalic vein and the SVC. Due to the overall con-
stellation, thrombosis of the right internal jugular vein and
partial thrombosis of the IVC, the decision was made to
choose the left jugular vein access and to combine SVC stent
implantation with suprarenal IVC filter insertion.
Following informed consent and local anesthesia, left
internal jugular vein puncture was performed under ultra-
sound guidance, and a 13-Fr sheath was inserted. Bicubital
mediastinal venogram confirmed compression of the con-
fluence of the right brachiocephalic vein and of the SVC by
a tumorous mass (Fig. 2). A 5000-unit bolus of heparin was
Fig. 1 Contrast-enhanced CT scan shows metastasis of the adrenal
gland with tumor invasion and partial thrombosis of the IVC
Fig. 2 Bicubital venogram demonstrates a tumorous mass lesion
compressing the confluence of the right brachiocephalic vein and the
SVC
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administered. After the length of the affected venous
confluence had been quantified with a calibrated pigtail
catheter, unilateral stent placement was undertaken.
Including the left brachiocephalic vein and SVC, a self-
expanding 22 · 90-mm sinus-Aorta-Stent (Optimed; Ett-
lingen, Germany) was placed just above the right atrial
level, with a good outflow of constrast medium (Fig. 3). In
continuation, a femoral venogram was performed and
exhibited tumor encasement of the IVC with partial
thrombosis at the level of the right suprarenal vein. A
retrievable vena cava filter (OPTEASE; Cordis, Roden,
The Netherlands) was then successfully inserted in a
suprarenal position using the left jugular access (Fig. 4). A
femoral approach for inferior vena caval infiltration was
avoided, so as not to trigger pulmonary embolism. At the
end of the intervention, full-scale heparinization (10 units/
kg body weight per 24 h) was initiated. Surgical port
implantation was performed 1 month later, and chemo-
therapy was recommenced. The patient had excellent relief
from her symptoms of SVCS, did not experience pulmo-
nary embolism during a follow-up of 6 months, and is in a
well general condition to date.
Discussion
Armand Trousseau was among the first authors who de-
scribed the relationship between cancer and VTE [12].
Matter of factly, his theories proved to be correct, when he
diagnosed himself with stomach cancer because of a
phlebitis on his left upper limb. In his honor, the coinci-
dence of cancer and VTE is called Trousseau syndrome,
belonging in the paraneoplastic sphere.
Jaffer et al. [2] calculated an elevated risk of thrombosis
in cancer patients, underlining the topicality of this issue.
Cancer patients with VTE further have an increased
probability of death compared to patients without a
thromboembolic event. This was proved by Sørensen et al.
[4] in an age-, gender-, and diagnosis-matched study. The
1-year survival rate among cancer patients without VTE
was 36%, versus 12% in patients with a thrombosis.
The development of thrombi can also be potentiated by
risk factors concerning treatment of the cancer [13, 14].
There are specific chemotherapeutic agents increasing the
incidence of thrombotic events, for example, tamoxifen in
the therapy of breast cancer or platinum-based therapies, 5-
fluorouracil, mitomycin, growth factors, and thalidomide.
Additionally, surgery, radiotherapy, and immobility may
initiate platelet aggregation [15].
Reviewing the literature for rectal, Rickles et al. [16]
listed the most frequently associated tumors with venous
thrombosis and revealed a 15.2% frequency for colon
cancer. In addition, Levitan et al. [17] showed that even 62
of 10,000 patients with rectal cancer develop a deep venous
thrombosis or pulmonary embolism. Specifically, rectal
cancer patients treated with a combination of fluorouracil
and leucovorin calcium, as in our case, because of colo-
rectal have a high risk (15%) for developing a VTE [3].
Different pathogenetic mechanisms have been described
to better understand the appearance of the hypercoagulable
state [18–20]. There are alterations in coagulation and
anticoagulant proteins and endothelial cells due to the
cytotoxic agents. In addition, the tumor itself can produce
Fig. 3 Bicubital venogram after unilateral stent placement within the
SVC and left brachiocephalic vein exhibits good restoration of flow
Fig. 4 Femoral venogram depicts successful suprarenal IVC filter
insertion just above the thrombus formation
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procoagulants and activate endogenous prothrombotic
factors [5, 6].
Venous thromboembolic events include superficial and
deep venous thrombosis, pulmonary embolism, and cath-
eter-associated thrombosis [15]. While deep vein throm-
bosis is the most common type of thromboembolic event,
SVCS is a rare complication.
A mediastinal invasion by bronchogenic carcinoma is
the most common cause of SVCS, accounting for 70%–
80% of all cases [10]. In our case, secondary spread of a
rectal tumor into the retrocaval, mediastinal lymph nodes
caused the syndrome, with congestion, edema of the face
and upper thorax, dyspnea, and dysphagia.
Different strategies for the treatment of SVCS exist [21–
23]. Many authors postulate chemotherapy and radiother-
apy as the standard treatment for SVCS in association with
malignant disease. Rodrigues et al. [21] treated SVCS with
three weekly high-dose fractions of 8 Gy and achieved a
partial response in 96% of all patients, and a complete
response in 56%. It must be considered that radiotherapy
may have side effects like fever, nausea, vomiting, and
mucositis, so that the patient loses further quality of life
[10].
Charnsangavej et al. [22] were the first to describe SVC
stenting as a further option. Since then, it has become a
standard treatment for this condition, because it provides
rapid relief of symptoms and the relief of SVCS in 80%–
95% of patients [23]. However, in cases of SVCS caused
by small cell carcinomas and lymphomas, chemotherapy is
recommended as the first-line treatment [21,23].
Concomitant treatment with anticoagulants after SVC
stenting may generally reduce the risk of deep venous
thrombosis in cancer patients [11, 22, 23]; moreover,
anticoagulation may induce delays of neoendothelial pro-
liferation. However, to date, a clear consensus concerning
the application and dosage of anticoagulant agents in
combination with SVC stent implantation does not exist.
Parallel to stents, IVC filters have developed increas-
ingly over the past two decades. Since their introduction in
1973, these filters have proven to be safe and effective in
the prevention of life-threatening pulmonary emboli [24].
Jarrett et al. [25] have shown that even advanced-stage
cancer patients may benefit from IVC filters. In a study by
Wallace et al. [24] the probability of survival at 30, 90, and
365 days in patients with gastrointestinal cancer was 79%,
54%, and 29%, respectively.
However, with regard to the clinical literature, the utility
of IVC filters is not universally accepted and results are
somewhat conflicting [26, 27]. In this context, a prospec-
tive, controlled clinical trial by Decousus et al. [27] re-
ported that inferior vena caval infiltration was useful in
preventing pulmonary embolism when combined with
anticoagulation. Nevertheless, an improvement in overall
mortality in patients with such a combined therapy did not
vary significantly from these patients with anticoagulation
alone. Most importantly, in patients with inferior vena
caval infiltration and anticoagulation a twofold increase in
recurrent deep venous thrombosis was observed in com-
parison to patients with anticoagulation alone.
Some authors have already reported that practice pat-
terns concerning IVC infilration were different and that
many indications for IVC filter insertion were a matter of
opinion [26–28]. With respect to Trousseau’s syndrome,
therapy with heparin anticoagulation alone is reported to be
effective and the therapy of choice [28]. Since this syn-
drome is a hypercoaguable state, inferior vena caval infil-
tration is said to be inadequate. In our case, it remains
speculative if IVC thrombosis was attributable to tumor
invasion or to sytemic hypercoaguability. Even though our
patient had formerly experienced right jugular vein
thrombosis, this complication might have been interpreted
as postsurgical syndrome. Therefore, the combination of
ICV filtration and anticoagulation after SVC stent
implantation seemed justified for us.
In conclusion, with regard to the clinical scenario de-
scribed herein, we see in SVC stenting and IVC filter
implantation combined with heparin anticoagulation an
efficient and safe approach to the therapy of SVCS and
IVC thrombosis to pave the way for further chemothera-
peutic treatment and to guarantee palliation in progressive
rectal cancer. Interventional radiologists as well as clini-
cians should be aware of such an extraordinary course of
malignant disease in order to provide effective manage-
ment.
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